Announcements
10/24/2011
Prima BioMed launches partnership with The City Hospital in Dubai Healthcare City to commercialise CVac™ in the Middle East
Australian health care company Prima BioMed Ltd (ASX: PRR) (Prima) is pleased to announce the formal launch of its partnership with The City Hospital in Dubai Healthcare City (DHCC) to make the CVac™ immunotherapy ovarian cancer vaccine commercially available in the Middle East region.
The program was officially launched yesterday, Sunday October 23, at a ceremony to mark the third anniversary of The City Hospital, and comes after Prima announced in May that it had been granted approval for the marketing and distribution of CVac™ in DHCC. Prima expects to be in a position to commence the first sales of CVac™ in DHCC before the end of 2011.
This represents a significant milestone for Prima. It is the first commercialisation of CVac™ anywhere in the world, and allows the Company to provide treatment for cancer patients in the Middle Eastern region and generate revenues in a growing health care market.
Article as pdf >> |
|